ID   HRL9
AC   CVCL_GZ13
SY   HRL9 HeLa
DR   TOKU-E; 4131
DR   Wikidata; Q54895232
RX   PubMed=10738580;
CC   Population: African American.
CC   Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16.
CC   Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR.
CC   Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del).
CC   Transfected with: UniProtKB; P08659; Firefly luciferase.
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2505 ! HR5
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 12
//
RX   PubMed=10738580; DOI=10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y;
RA   Freundlieb S., Schirra-Muller C., Bujard H.;
RT   "A tetracycline controlled activation/repression system with increased
RT   potential for gene transfer into mammalian cells.";
RL   J. Gene Med. 1:4-12(1999).
//